论文信息 - A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma - 字舞流文

A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos | J. Cavenagh | H. van de Velde | R. Orlowski | T. Robak | T. Masszi | J. Bladé | Â. Maiolino | I. Špička | T. Puchalski | Hong Xie | R. Bandekar | H. Sutherland | J. Rossi | L. Gercheva | M. Reddy | C. Williams | V. Goranova-Marinova | O. Samoylova | Alexander Suvorov | H. V. D. van de Velde | A. Suvorov | H. Xie | Cathy D. Williams | Heather Sutherland | Tadeusz J. Robak | James D. Cavenagh | Olga Samoylova | Hong Xie | Jean‐Franςois Rossi | Tadeusz Robak